Deerfield Management Company, L.P. (Series C) Nuvation Bio Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $4.76 Billion
- Q2 2024
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 262,205 shares of NUVB stock, worth $613,559. This represents 0.02% of its overall portfolio holdings.
Number of Shares
262,205Holding current value
$613,559% of portfolio
0.02%Shares
6 transactions
Others Institutions Holding NUVB
# of Institutions
152Shares Held
123MCall Options Held
9.7KPut Options Held
6.5K-
Eco R1 Capital, LLC San Francisco, CA19.2MShares$45 Million1.98% of portfolio
-
Black Rock Inc. New York, NY16.2MShares$38 Million0.0% of portfolio
-
Omega Fund Management, LLC Boston, MA13.3MShares$31.1 Million50.57% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$23.7 Million0.0% of portfolio
-
Decheng Capital LLC Menlo Park, CA6.95MShares$16.3 Million6.22% of portfolio
About Nuvation Bio Inc.
- Ticker NUVB
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 217,244,000
- Market Cap $508M
- Description
- Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...